GlassScriptPhysician profile
Daniel C Traviesa
NPI 1679549422
$8,151.78
in general payments reported to CMS, 2019-2025
47 companies · $56.62 in 2025
The $56.62 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,412 · 2020: $2,765 · 2021: $796 · 2022: $34.04 · 2023: $67.15 · 2024: $21.23 · 2025: $56.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $778.77 | 2019-2025 | |
| Amgen INC. | $703.00 | 2019-2021 | |
| Allergan, INC. | $700.14 | 2019-2021 | |
| Ucb, INC. | $614.65 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $604.93 | 2019-2021 | |
| Genzyme Corporation | $500.39 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $343.63 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $298.74 | 2019-2020 | |
| Abbvie INC. | $297.88 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $266.46 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $263.03 | 2019-2021 | |
| Emd Serono, INC. | $251.26 | 2019-2020 | |
| Acorda Therapeutics, INC | $227.97 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $220.82 | 2019-2020 | |
| Harmony Biosciences LLC | $195.17 | 2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Traviesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.